Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 168 entries
Sorted by: Best Match Show Resources per page
Improving women's health in low-income and middle-income countries. Part I: challenges and priorities.

Nuclear medicine communications

Mariani G, Kasznia-Brown J, Paez D, Mikhail MN, H Salama D, Bhatla N, Erba PA, Kashyap R.
PMID: 28922336
Nucl Med Commun. 2017 Dec;38(12):1019-1023. doi: 10.1097/MNM.0000000000000751.

No abstract available.

Cite
Mariani G, Kasznia-Brown J, Paez D, et al. Improving women's health in low-income and middle-income countries. Part I: challenges and priorities. Nucl Med Commun. 2017;38(12):1019-1023doi: 10.1097/MNM.0000000000000751.
Mariani, G., Kasznia-Brown, J., Paez, D., Mikhail, M. N., H Salama, D., Bhatla, N., Erba, P. A., & Kashyap, R. (2017). Improving women's health in low-income and middle-income countries. Part I: challenges and priorities. Nuclear medicine communications, 38(12), 1019-1023. https://doi.org/10.1097/MNM.0000000000000751
Mariani, Giuliano, et al. "Improving women's health in low-income and middle-income countries. Part I: challenges and priorities." Nuclear medicine communications vol. 38,12 (2017): 1019-1023. doi: https://doi.org/10.1097/MNM.0000000000000751
Mariani G, Kasznia-Brown J, Paez D, Mikhail MN, H Salama D, Bhatla N, Erba PA, Kashyap R. Improving women's health in low-income and middle-income countries. Part I: challenges and priorities. Nucl Med Commun. 2017 Dec;38(12):1019-1023. doi: 10.1097/MNM.0000000000000751. PMID: 28922336; PMCID: PMC5704651.
Copy Download .nbib Format: NLM
British Nuclear Medicine Society Autumn Meeting 2021.

Nuclear medicine communications

[No authors listed]
PMID: 34528932
Nucl Med Commun. 2021 Oct 01;42(10):1162-1185. doi: 10.1097/MNM.0000000000001479.

No abstract available.

Cite
British Nuclear Medicine Society Autumn Meeting 2021. Nucl Med Commun. 2021;42(10):1162-1185doi: 10.1097/MNM.0000000000001479.
(2021). British Nuclear Medicine Society Autumn Meeting 2021. Nuclear medicine communications, 42(10), 1162-1185. https://doi.org/10.1097/MNM.0000000000001479
"British Nuclear Medicine Society Autumn Meeting 2021." Nuclear medicine communications vol. 42,10 (2021): 1162-1185. doi: https://doi.org/10.1097/MNM.0000000000001479
British Nuclear Medicine Society Autumn Meeting 2021. Nucl Med Commun. 2021 Oct 01;42(10):1162-1185. doi: 10.1097/MNM.0000000000001479. PMID: 34528932.
Copy Download .nbib Format: NLM
99mTc-HMPAO-WBC SPECT/CT versus 18F-FDG-WBC PET/CT in chronic prosthetic joint infection: a pilot study.

Nuclear medicine communications

Teiler J, Ahl M, Åkerlund B, Brismar H, Holstensson M, Gabrielson S, Hedlund H, Axelsson R.
PMID: 34678830
Nucl Med Commun. 2022 Feb 01;43(2):193-200. doi: 10.1097/MNM.0000000000001502.

PURPOSE: The aim of this study was to compare 99mTc-HMPAO-WBC-SPECT/CT combined with 99mTc-nanocollloid SPECT/CT and 18F-FDG-WBC-PET/CT combined with 99mTc-Nanocollloid SPECT/CT for the diagnosis and treatment evaluation of chronic prosthetic joint infection (PJI).METHODS: Patients with suspected chronic PJI were examined...

Cite
Teiler J, Ahl M, Åkerlund B, et al. 99mTc-HMPAO-WBC SPECT/CT versus 18F-FDG-WBC PET/CT in chronic prosthetic joint infection: a pilot study. Nucl Med Commun. 2022;43(2):193-200doi: 10.1097/MNM.0000000000001502.
Teiler, J., Ahl, M., Åkerlund, B., Brismar, H., Holstensson, M., Gabrielson, S., Hedlund, H., & Axelsson, R. (2022). 99mTc-HMPAO-WBC SPECT/CT versus 18F-FDG-WBC PET/CT in chronic prosthetic joint infection: a pilot study. Nuclear medicine communications, 43(2), 193-200. https://doi.org/10.1097/MNM.0000000000001502
Teiler, Johan, et al. "99mTc-HMPAO-WBC SPECT/CT versus 18F-FDG-WBC PET/CT in chronic prosthetic joint infection: a pilot study." Nuclear medicine communications vol. 43,2 (2022): 193-200. doi: https://doi.org/10.1097/MNM.0000000000001502
Teiler J, Ahl M, Åkerlund B, Brismar H, Holstensson M, Gabrielson S, Hedlund H, Axelsson R. 99mTc-HMPAO-WBC SPECT/CT versus 18F-FDG-WBC PET/CT in chronic prosthetic joint infection: a pilot study. Nucl Med Commun. 2022 Feb 01;43(2):193-200. doi: 10.1097/MNM.0000000000001502. PMID: 34678830.
Copy Download .nbib Format: NLM
Abstracts: British Nuclear Medicine Society Online Spring Meeting 18th-19th May 2021.

Nuclear medicine communications

[No authors listed]
PMID: 33821843
Nucl Med Commun. 2021 May 01;42(5):575-581. doi: 10.1097/MNM.0000000000001180.

No abstract available.

Cite
Abstracts: British Nuclear Medicine Society Online Spring Meeting 18th-19th May 2021. Nucl Med Commun. 2021;42(5):575-581doi: 10.1097/MNM.0000000000001180.
(2021). Abstracts: British Nuclear Medicine Society Online Spring Meeting 18th-19th May 2021. Nuclear medicine communications, 42(5), 575-581. https://doi.org/10.1097/MNM.0000000000001180
"Abstracts: British Nuclear Medicine Society Online Spring Meeting 18th-19th May 2021." Nuclear medicine communications vol. 42,5 (2021): 575-581. doi: https://doi.org/10.1097/MNM.0000000000001180
Abstracts: British Nuclear Medicine Society Online Spring Meeting 18th-19th May 2021. Nucl Med Commun. 2021 May 01;42(5):575-581. doi: 10.1097/MNM.0000000000001180. PMID: 33821843.
Copy Download .nbib Format: NLM
Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism.

Nuclear medicine communications

O' Doherty J, O' Doherty S, Robins EG, Reilhac A.
PMID: 34406144
Nucl Med Commun. 2021 Aug 17; doi: 10.1097/MNM.0000000000001477. Epub 2021 Aug 17.

OBJECTIVE: 11C-metomidate (11C-MTO) PET-computed tomography (CT) imaging has shown good sensitivity and specificity for the classification of bilateral or unilateral overexpression of aldosterone. This work seeks to investigate the usefulness of parametric maps via kinetic modeling of 11C-metomidate data...

Cite
O' Doherty J, O' Doherty S, Robins EG, et al. Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism. Nucl Med Commun. 2021;doi: 10.1097/MNM.0000000000001477.
O' Doherty, J., O' Doherty, S., Robins, E. G., & Reilhac, A. (2021). Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism. Nuclear medicine communications, . https://doi.org/10.1097/MNM.0000000000001477
O' Doherty, Jim, et al. "Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism." Nuclear medicine communications vol. (2021). doi: https://doi.org/10.1097/MNM.0000000000001477
O' Doherty J, O' Doherty S, Robins EG, Reilhac A. Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism. Nucl Med Commun. 2021 Aug 17; doi: 10.1097/MNM.0000000000001477. Epub 2021 Aug 17. PMID: 34406144.
Copy Download .nbib Format: NLM
Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients.

Nuclear medicine communications

Kapsoritakis N, Stathaki M, Bourogianni O, Tsaroucha A, Papadaki E, Simos P, Koukouraki S.
PMID: 34149007
Nucl Med Commun. 2021 Nov 01;42(11):1202-1208. doi: 10.1097/MNM.0000000000001455.

OBJECTIVES: We investigated the clinical impact of single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy combined with 16-slice CT on metastatic workup and treatment planning in a large cancer patient series.METHODS: Between January 2019 and January 2020, a total...

Cite
Kapsoritakis N, Stathaki M, Bourogianni O, et al. Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients. Nucl Med Commun. 2021;42(11):1202-1208doi: 10.1097/MNM.0000000000001455.
Kapsoritakis, N., Stathaki, M., Bourogianni, O., Tsaroucha, A., Papadaki, E., Simos, P., & Koukouraki, S. (2021). Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients. Nuclear medicine communications, 42(11), 1202-1208. https://doi.org/10.1097/MNM.0000000000001455
Kapsoritakis, Nikolaos, et al. "Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients." Nuclear medicine communications vol. 42,11 (2021): 1202-1208. doi: https://doi.org/10.1097/MNM.0000000000001455
Kapsoritakis N, Stathaki M, Bourogianni O, Tsaroucha A, Papadaki E, Simos P, Koukouraki S. Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients. Nucl Med Commun. 2021 Nov 01;42(11):1202-1208. doi: 10.1097/MNM.0000000000001455. PMID: 34149007.
Copy Download .nbib Format: NLM
The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors.

Nuclear medicine communications

Metser U, Eshet Y, Ortega C, Veit-Haibach P, Liu A, K S Wong R.
PMID: 34887370
Nucl Med Commun. 2022 Jan 01;43(1):73-77. doi: 10.1097/MNM.0000000000001488.

PURPOSE: To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with 177Lu-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline 68Ga-DOTATATE PET and their response to therapy. A...

Cite
Metser U, Eshet Y, Ortega C, et al. The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nucl Med Commun. 2022;43(1):73-77doi: 10.1097/MNM.0000000000001488.
Metser, U., Eshet, Y., Ortega, C., Veit-Haibach, P., Liu, A., & K S Wong, R. (2022). The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nuclear medicine communications, 43(1), 73-77. https://doi.org/10.1097/MNM.0000000000001488
Metser, Ur, et al. "The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors." Nuclear medicine communications vol. 43,1 (2022): 73-77. doi: https://doi.org/10.1097/MNM.0000000000001488
Metser U, Eshet Y, Ortega C, Veit-Haibach P, Liu A, K S Wong R. The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nucl Med Commun. 2022 Jan 01;43(1):73-77. doi: 10.1097/MNM.0000000000001488. PMID: 34887370.
Copy Download .nbib Format: NLM
Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses.

Nuclear medicine communications

Sugawara H, Ito K, Watanabe H, Morita T, Yatabe Y, Watanabe SI, Kusumoto M.
PMID: 34887372
Nucl Med Commun. 2022 Jan 01;43(1):92-99. doi: 10.1097/MNM.0000000000001483.

OBJECTIVES: To investigate the clinical usefulness of 18F-fluorodeoxyglucose (FDG) PET/MRI in differentiating anterior mediastinal lesions, including small ones.MATERIAL AND METHODS: Among 96 patients who underwent 18F-FDG PET/MRI screening for anterior mediastinal lesions, we retrospectively reviewed images of 42 patients...

Cite
Sugawara H, Ito K, Watanabe H, et al. Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses. Nucl Med Commun. 2022;43(1):92-99doi: 10.1097/MNM.0000000000001483.
Sugawara, H., Ito, K., Watanabe, H., Morita, T., Yatabe, Y., Watanabe, S. I., & Kusumoto, M. (2022). Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses. Nuclear medicine communications, 43(1), 92-99. https://doi.org/10.1097/MNM.0000000000001483
Sugawara, Haruto, et al. "Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses." Nuclear medicine communications vol. 43,1 (2022): 92-99. doi: https://doi.org/10.1097/MNM.0000000000001483
Sugawara H, Ito K, Watanabe H, Morita T, Yatabe Y, Watanabe SI, Kusumoto M. Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses. Nucl Med Commun. 2022 Jan 01;43(1):92-99. doi: 10.1097/MNM.0000000000001483. PMID: 34887372.
Copy Download .nbib Format: NLM
Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients.

Nuclear medicine communications

Xue XQ, Yu WJ, Shao XL, Li XF, Niu R, Zhang FF, Shi YM, Wang YT.
PMID: 34954765
Nucl Med Commun. 2021 Dec 23; doi: 10.1097/MNM.0000000000001523. Epub 2021 Dec 23.

OBJECTIVE: The aim of the study was to construct and validate 18F-fluorodeoxyglucose (18F-FDG) PET-based radiomics nomogram and use it to predict N2-3b lymph node metastasis in Chinese patients with gastric cancer (GC).METHODS: A total of 127 patients with pathologically...

Cite
Xue XQ, Yu WJ, Shao XL, et al. Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients. Nucl Med Commun. 2021;doi: 10.1097/MNM.0000000000001523.
Xue, X. Q., Yu, W. J., Shao, X. L., Li, X. F., Niu, R., Zhang, F. F., Shi, Y. M., & Wang, Y. T. (2021). Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients. Nuclear medicine communications, . https://doi.org/10.1097/MNM.0000000000001523
Xue, Xiu-Qing, et al. "Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients." Nuclear medicine communications vol. (2021). doi: https://doi.org/10.1097/MNM.0000000000001523
Xue XQ, Yu WJ, Shao XL, Li XF, Niu R, Zhang FF, Shi YM, Wang YT. Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients. Nucl Med Commun. 2021 Dec 23; doi: 10.1097/MNM.0000000000001523. Epub 2021 Dec 23. PMID: 34954765.
Copy Download .nbib Format: NLM
Evaluation of 68Ga-PSMA PET/CT with Volumetric Parameters for Staging of Prostate Cancer Patients: Erratum.

Nuclear medicine communications

[No authors listed]
PMID: 34528933
Nucl Med Commun. 2021 Oct 01;42(10):1186. doi: 10.1097/MNM.0000000000001482.

No abstract available.

Cite
Evaluation of 68Ga-PSMA PET/CT with Volumetric Parameters for Staging of Prostate Cancer Patients: Erratum. Nucl Med Commun. 2021;42(10):1186doi: 10.1097/MNM.0000000000001482.
(2021). Evaluation of 68Ga-PSMA PET/CT with Volumetric Parameters for Staging of Prostate Cancer Patients: Erratum. Nuclear medicine communications, 42(10), 1186. https://doi.org/10.1097/MNM.0000000000001482
"Evaluation of 68Ga-PSMA PET/CT with Volumetric Parameters for Staging of Prostate Cancer Patients: Erratum." Nuclear medicine communications vol. 42,10 (2021): 1186. doi: https://doi.org/10.1097/MNM.0000000000001482
Evaluation of 68Ga-PSMA PET/CT with Volumetric Parameters for Staging of Prostate Cancer Patients: Erratum. Nucl Med Commun. 2021 Oct 01;42(10):1186. doi: 10.1097/MNM.0000000000001482. PMID: 34528933.
Copy Download .nbib Format: NLM
Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma.

Nuclear medicine communications

Coskun N, Okudan B, Uncu D, Kitapci MT.
PMID: 34075009
Nucl Med Commun. 2021 Nov 01;42(11):1227-1232. doi: 10.1097/MNM.0000000000001447.

PURPOSE: We sought to investigate the performance of radiomics analysis on baseline 18F-FDG PET/CT for predicting response to first-line chemotherapy in diffuse large B-cell lymphoma (DLBCL).MATERIAL AND METHODS: Forty-five patients who received first-line rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone...

Cite
Coskun N, Okudan B, Uncu D, et al. Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma. Nucl Med Commun. 2021;42(11):1227-1232doi: 10.1097/MNM.0000000000001447.
Coskun, N., Okudan, B., Uncu, D., & Kitapci, M. T. (2021). Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma. Nuclear medicine communications, 42(11), 1227-1232. https://doi.org/10.1097/MNM.0000000000001447
Coskun, Nazim, et al. "Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma." Nuclear medicine communications vol. 42,11 (2021): 1227-1232. doi: https://doi.org/10.1097/MNM.0000000000001447
Coskun N, Okudan B, Uncu D, Kitapci MT. Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma. Nucl Med Commun. 2021 Nov 01;42(11):1227-1232. doi: 10.1097/MNM.0000000000001447. PMID: 34075009.
Copy Download .nbib Format: NLM
Comparison of an in-house acquired brain F-18 FDG PET normal database with commercially available normal data.

Nuclear medicine communications

Waterschoot R, D'Asseler Y, Goethals I.
PMID: 33867483
Nucl Med Commun. 2021 Sep 01;42(9):1039-1044. doi: 10.1097/MNM.0000000000001427.

INTRODUCTION: Current guidelines recommend the use of semiautomated assessment of F-18 FDG PET brain studies. Accuracy is influenced by the normal data, which requires knowledge of the included subjects and how they were acquired. Due to confidentiality, such information...

Cite
Waterschoot R, D'Asseler Y, Goethals I. Comparison of an in-house acquired brain F-18 FDG PET normal database with commercially available normal data. Nucl Med Commun. 2021;42(9):1039-1044doi: 10.1097/MNM.0000000000001427.
Waterschoot, R., D'Asseler, Y., & Goethals, I. (2021). Comparison of an in-house acquired brain F-18 FDG PET normal database with commercially available normal data. Nuclear medicine communications, 42(9), 1039-1044. https://doi.org/10.1097/MNM.0000000000001427
Waterschoot, Robbe, et al. "Comparison of an in-house acquired brain F-18 FDG PET normal database with commercially available normal data." Nuclear medicine communications vol. 42,9 (2021): 1039-1044. doi: https://doi.org/10.1097/MNM.0000000000001427
Waterschoot R, D'Asseler Y, Goethals I. Comparison of an in-house acquired brain F-18 FDG PET normal database with commercially available normal data. Nucl Med Commun. 2021 Sep 01;42(9):1039-1044. doi: 10.1097/MNM.0000000000001427. PMID: 33867483.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 168 entries